Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)

ReCOV (recombinant two-component COVID-19 vaccine (CHO cell)) - Jiangsu Rec-Biotech

http://clinicaltrials.gov/ct2/show/NCT05398848

Feb 29, 2024